<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609388</url>
  </required_header>
  <id_info>
    <org_study_id>TX 001/07</org_study_id>
    <nct_id>NCT00609388</nct_id>
  </id_info>
  <brief_title>Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation</brief_title>
  <acronym>TAC-Infusion</acronym>
  <official_title>Evaluation of Tacrolimus (PrografÂ®) Intraportal Infusion During the Implantation and the Protective Effect on Ischemia-reperfusion Injury in Orthotopic Liver Transplant Recipients - Single Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The evaluation of the efficacy of an intraportal infusion with Tacrolimus, at the time of
      liver graft implantation, compared to a control group without immunosuppressive intraportal
      infusion (Placebo: Saline solution 0.9%) with respect to the initial liver function measured
      by the parameters of the liver function (LFP): AST (U/L), ALT (U/L), total Bilirubin (mg/dL)
      and the coagulation factors: NT (%), PTT (s), INR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>initial liver function measured by the parameters of the liver function (LFP): AST (U/L), ALT (U/L), total Bilirubin (mg/dL) and the coagulation factors: NT (%), PTT(s),INR.</measure>
    <time_frame>Day 1,2,3; Weeks 6 and 12 post OLT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum parameters: TNF alpha, IL1, IL6</measure>
    <time_frame>within the first 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathology (before and after reperfusion)</measure>
    <time_frame>within the first 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of rejection episodes</measure>
    <time_frame>within the first 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function (Serum) und graft survival at 3 months post Tx</measure>
    <time_frame>within the first 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival at 3 months post Tx</measure>
    <time_frame>within the first 3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL</description>
    <arm_group_label>A</arm_group_label>
    <other_name>PROGRAF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution 0.9% (250mL)</intervention_name>
    <description>intraoperative intraportal infusion of Saline solution 0.9% (250mL)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multi organ transplantation or retransplantation

          -  ABO incompatible donor organ recipients- Patients, who are listed on the liver
             transplant-waiting list at the Vienna General Hospital and who fulfill the clinical
             requirements (local allocation)

          -  Written informed consent

          -  Age &gt; 18

          -  First transplantation

        Exclusion Criteria:

          -  Fulminant failure of the liver

          -  Liver-Living donor recipients

          -  pregnant or nursing women

          -  Allergy/Intolerance to antimetabolites, HCO-60, EL Cremophor or similar
             compounds,Steroids or macrolide antibiotics

          -  HIV-positive donors or recipients

          -  Participants of another clinical study

          -  Patient has any form of substance abuse, psychiatric disorder or condition, which, in
             the opinion of the investigator, may invalidate communication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bodingbauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>St Peter SD, Post DJ, Rodriguez-Davalos MI, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transpl. 2003 Feb;9(2):144-9.</citation>
    <PMID>12548508</PMID>
  </results_reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Martin Bodingbauer</name_title>
    <organization>Medical University of Vienna / Dep. of Transplantation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

